Vertex Pharmaceuticals VRTX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's accounts receivable?
- Vertex Pharmaceuticals (VRTX) reported accounts receivable of $2B in Q1 2026.
- How has Vertex Pharmaceuticals's accounts receivable changed year-over-year?
- Vertex Pharmaceuticals's accounts receivable increased by 10.6% year-over-year, from $1.81B to $2B.
- What is the long-term trend for Vertex Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's accounts receivable has grown at a 18.3% compound annual growth rate (CAGR), from $885.4M to $2.05B.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.